Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023
Background The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated. Key Points of the Guidelines Update Version 12.0 of the guidelines recommend the same six first‐line treatment options for antiretroviral treatment (ART)‐...
Gespeichert in:
| Veröffentlicht in: | HIV medicine 2023-11, Vol.24 (11), p.1126-1136 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1136 |
|---|---|
| container_issue | 11 |
| container_start_page | 1126 |
| container_title | HIV medicine |
| container_volume | 24 |
| creator | Ambrosioni, Juan Levi, Laura Alagaratnam, Jasmini Van Bremen, Kathrin Mastrangelo, Andrea Waalewijn, Hylke Molina, Jean‐Michel Guaraldi, Giovanni Winston, Alan Boesecke, Christoph Cinque, Paola Bamford, Alasdair Calmy, Alexandra Marzolini, Catia Martínez, Esteban Oprea, Cristiana Welch, Steven Koval, Anna Mendao, Luis Rockstroh, Jürgen K. |
| description | Background
The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.
Key Points of the Guidelines Update
Version 12.0 of the guidelines recommend the same six first‐line treatment options for antiretroviral treatment (ART)‐naïve adults as versions 11.0 and 11.1: tenofovir‐based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long‐acting section has been expanded in the ART and drug–drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti‐infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient‐reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir‐free two‐drug regimens in people with isolated anti‐hepatitis B core antibodies are provided. In the opportunistic infections and COVID‐19 panel, guidance on the management of COVID‐19 in people with HIV has been updated according to the most up‐to‐date evidence, and a new section on monkeypox has been added.
Conclusions
In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online. |
| doi_str_mv | 10.1111/hiv.13542 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2878713351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2889744892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3882-e56a793670ceba918dca7cd90bfc472247ad93b59b931fe886964a3be006bb033</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgiveFLyABN7qYNrdOkqXUqgVFpOp2yGTOaMp0UpNOpW9vbNWFYDYnHD5-Dj9CJ5T0aHr9N7fsUT4QbAvtU5GrjDLNt9d_kbE8Z3voIMYpIVRyTXbRHpdKaMHZPnq8N1MfcICli863eAlhPSnrEexrvHgDPOqCn4Np8eX4aoKHjWudNQ2eeOtgscKvnasgLSFiRhg_Qju1aSIcf89D9Hw9ehreZncPN-Ph5V1muVIsg0FupOa5JBZKo6mqrJG20qSsrZCMCWkqzcuBLjWnNSiV61wYXgIheVkSzg_R-SZ3Hvx7B3FRzFy00DSmBd_FgimpJOV8QBM9-0Onvgttui4ppaUQSrOkLjbKBh9jgLqYBzczYVVQUnz1XKSei3XPyZ5-J3blDKpf-VNsAv0N-HANrP5PKm7HL5vIT05wg_0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2889744892</pqid></control><display><type>article</type><title>Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023</title><source>Access via Wiley Online Library</source><source>MEDLINE</source><creator>Ambrosioni, Juan ; Levi, Laura ; Alagaratnam, Jasmini ; Van Bremen, Kathrin ; Mastrangelo, Andrea ; Waalewijn, Hylke ; Molina, Jean‐Michel ; Guaraldi, Giovanni ; Winston, Alan ; Boesecke, Christoph ; Cinque, Paola ; Bamford, Alasdair ; Calmy, Alexandra ; Marzolini, Catia ; Martínez, Esteban ; Oprea, Cristiana ; Welch, Steven ; Koval, Anna ; Mendao, Luis ; Rockstroh, Jürgen K.</creator><creatorcontrib>Ambrosioni, Juan ; Levi, Laura ; Alagaratnam, Jasmini ; Van Bremen, Kathrin ; Mastrangelo, Andrea ; Waalewijn, Hylke ; Molina, Jean‐Michel ; Guaraldi, Giovanni ; Winston, Alan ; Boesecke, Christoph ; Cinque, Paola ; Bamford, Alasdair ; Calmy, Alexandra ; Marzolini, Catia ; Martínez, Esteban ; Oprea, Cristiana ; Welch, Steven ; Koval, Anna ; Mendao, Luis ; Rockstroh, Jürgen K. ; EACS Governing Board ; The EACS Governing Board</creatorcontrib><description>Background
The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.
Key Points of the Guidelines Update
Version 12.0 of the guidelines recommend the same six first‐line treatment options for antiretroviral treatment (ART)‐naïve adults as versions 11.0 and 11.1: tenofovir‐based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long‐acting section has been expanded in the ART and drug–drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti‐infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient‐reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir‐free two‐drug regimens in people with isolated anti‐hepatitis B core antibodies are provided. In the opportunistic infections and COVID‐19 panel, guidance on the management of COVID‐19 in people with HIV has been updated according to the most up‐to‐date evidence, and a new section on monkeypox has been added.
Conclusions
In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.</description><identifier>ISSN: 1464-2662</identifier><identifier>ISSN: 1468-1293</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/hiv.13542</identifier><identifier>PMID: 37849432</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Abacavir ; Acquired immune deficiency syndrome ; Acquired Immunodeficiency Syndrome - drug therapy ; Adolescent ; Adolescents ; Adult ; AIDS ; AIDS-Related Opportunistic Infections - drug therapy ; Algorithms ; Anti-HIV Agents - therapeutic use ; Anti-Retroviral Agents - therapeutic use ; Antibodies ; Antiretroviral agents ; Antiretroviral therapy ; Breast feeding ; Cancer screening ; Child ; Cognitive ability ; Comorbidity ; COVID-19 ; Diabetes mellitus ; Disease transmission ; Drug interaction ; Drug interactions ; EACS ; Emtricitabine ; European AIDS Clinical Society ; Guidelines ; Hepatitis ; Hepatitis B ; Hepatitis C ; Hepatitis C - drug therapy ; HIV ; HIV Infections - diagnosis ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Infections ; Integrase ; Lamivudine ; Lamivudine - therapeutic use ; major updates ; Medical screening ; Monkeypox ; Mpox ; Mpox (monkeypox) ; Practice Guidelines as Topic ; Sexual health ; Sexually transmitted diseases ; STD ; Tenofovir ; Tenofovir - therapeutic use ; V12.0 ; Vaccination ; Vaccines ; Viral diseases ; Viruses</subject><ispartof>HIV medicine, 2023-11, Vol.24 (11), p.1126-1136</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd on behalf of British HIV Association.</rights><rights>2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3882-e56a793670ceba918dca7cd90bfc472247ad93b59b931fe886964a3be006bb033</citedby><cites>FETCH-LOGICAL-c3882-e56a793670ceba918dca7cd90bfc472247ad93b59b931fe886964a3be006bb033</cites><orcidid>0000-0002-5847-8416 ; 0000-0003-2448-5957 ; 0000-0002-5135-8729 ; 0000-0001-9931-6686 ; 0000-0003-2256-423X ; 0000-0002-5724-3914 ; 0000-0003-4764-229X ; 0000-0001-9581-2527</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhiv.13542$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhiv.13542$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37849432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ambrosioni, Juan</creatorcontrib><creatorcontrib>Levi, Laura</creatorcontrib><creatorcontrib>Alagaratnam, Jasmini</creatorcontrib><creatorcontrib>Van Bremen, Kathrin</creatorcontrib><creatorcontrib>Mastrangelo, Andrea</creatorcontrib><creatorcontrib>Waalewijn, Hylke</creatorcontrib><creatorcontrib>Molina, Jean‐Michel</creatorcontrib><creatorcontrib>Guaraldi, Giovanni</creatorcontrib><creatorcontrib>Winston, Alan</creatorcontrib><creatorcontrib>Boesecke, Christoph</creatorcontrib><creatorcontrib>Cinque, Paola</creatorcontrib><creatorcontrib>Bamford, Alasdair</creatorcontrib><creatorcontrib>Calmy, Alexandra</creatorcontrib><creatorcontrib>Marzolini, Catia</creatorcontrib><creatorcontrib>Martínez, Esteban</creatorcontrib><creatorcontrib>Oprea, Cristiana</creatorcontrib><creatorcontrib>Welch, Steven</creatorcontrib><creatorcontrib>Koval, Anna</creatorcontrib><creatorcontrib>Mendao, Luis</creatorcontrib><creatorcontrib>Rockstroh, Jürgen K.</creatorcontrib><creatorcontrib>EACS Governing Board</creatorcontrib><creatorcontrib>The EACS Governing Board</creatorcontrib><title>Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Background
The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.
Key Points of the Guidelines Update
Version 12.0 of the guidelines recommend the same six first‐line treatment options for antiretroviral treatment (ART)‐naïve adults as versions 11.0 and 11.1: tenofovir‐based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long‐acting section has been expanded in the ART and drug–drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti‐infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient‐reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir‐free two‐drug regimens in people with isolated anti‐hepatitis B core antibodies are provided. In the opportunistic infections and COVID‐19 panel, guidance on the management of COVID‐19 in people with HIV has been updated according to the most up‐to‐date evidence, and a new section on monkeypox has been added.
Conclusions
In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.</description><subject>Abacavir</subject><subject>Acquired immune deficiency syndrome</subject><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Adolescent</subject><subject>Adolescents</subject><subject>Adult</subject><subject>AIDS</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>Algorithms</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antibodies</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral therapy</subject><subject>Breast feeding</subject><subject>Cancer screening</subject><subject>Child</subject><subject>Cognitive ability</subject><subject>Comorbidity</subject><subject>COVID-19</subject><subject>Diabetes mellitus</subject><subject>Disease transmission</subject><subject>Drug interaction</subject><subject>Drug interactions</subject><subject>EACS</subject><subject>Emtricitabine</subject><subject>European AIDS Clinical Society</subject><subject>Guidelines</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>HIV</subject><subject>HIV Infections - diagnosis</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Integrase</subject><subject>Lamivudine</subject><subject>Lamivudine - therapeutic use</subject><subject>major updates</subject><subject>Medical screening</subject><subject>Monkeypox</subject><subject>Mpox</subject><subject>Mpox (monkeypox)</subject><subject>Practice Guidelines as Topic</subject><subject>Sexual health</subject><subject>Sexually transmitted diseases</subject><subject>STD</subject><subject>Tenofovir</subject><subject>Tenofovir - therapeutic use</subject><subject>V12.0</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Viruses</subject><issn>1464-2662</issn><issn>1468-1293</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp10MtKAzEUBuAgiveFLyABN7qYNrdOkqXUqgVFpOp2yGTOaMp0UpNOpW9vbNWFYDYnHD5-Dj9CJ5T0aHr9N7fsUT4QbAvtU5GrjDLNt9d_kbE8Z3voIMYpIVRyTXbRHpdKaMHZPnq8N1MfcICli863eAlhPSnrEexrvHgDPOqCn4Np8eX4aoKHjWudNQ2eeOtgscKvnasgLSFiRhg_Qju1aSIcf89D9Hw9ehreZncPN-Ph5V1muVIsg0FupOa5JBZKo6mqrJG20qSsrZCMCWkqzcuBLjWnNSiV61wYXgIheVkSzg_R-SZ3Hvx7B3FRzFy00DSmBd_FgimpJOV8QBM9-0Onvgttui4ppaUQSrOkLjbKBh9jgLqYBzczYVVQUnz1XKSei3XPyZ5-J3blDKpf-VNsAv0N-HANrP5PKm7HL5vIT05wg_0</recordid><startdate>202311</startdate><enddate>202311</enddate><creator>Ambrosioni, Juan</creator><creator>Levi, Laura</creator><creator>Alagaratnam, Jasmini</creator><creator>Van Bremen, Kathrin</creator><creator>Mastrangelo, Andrea</creator><creator>Waalewijn, Hylke</creator><creator>Molina, Jean‐Michel</creator><creator>Guaraldi, Giovanni</creator><creator>Winston, Alan</creator><creator>Boesecke, Christoph</creator><creator>Cinque, Paola</creator><creator>Bamford, Alasdair</creator><creator>Calmy, Alexandra</creator><creator>Marzolini, Catia</creator><creator>Martínez, Esteban</creator><creator>Oprea, Cristiana</creator><creator>Welch, Steven</creator><creator>Koval, Anna</creator><creator>Mendao, Luis</creator><creator>Rockstroh, Jürgen K.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5847-8416</orcidid><orcidid>https://orcid.org/0000-0003-2448-5957</orcidid><orcidid>https://orcid.org/0000-0002-5135-8729</orcidid><orcidid>https://orcid.org/0000-0001-9931-6686</orcidid><orcidid>https://orcid.org/0000-0003-2256-423X</orcidid><orcidid>https://orcid.org/0000-0002-5724-3914</orcidid><orcidid>https://orcid.org/0000-0003-4764-229X</orcidid><orcidid>https://orcid.org/0000-0001-9581-2527</orcidid></search><sort><creationdate>202311</creationdate><title>Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023</title><author>Ambrosioni, Juan ; Levi, Laura ; Alagaratnam, Jasmini ; Van Bremen, Kathrin ; Mastrangelo, Andrea ; Waalewijn, Hylke ; Molina, Jean‐Michel ; Guaraldi, Giovanni ; Winston, Alan ; Boesecke, Christoph ; Cinque, Paola ; Bamford, Alasdair ; Calmy, Alexandra ; Marzolini, Catia ; Martínez, Esteban ; Oprea, Cristiana ; Welch, Steven ; Koval, Anna ; Mendao, Luis ; Rockstroh, Jürgen K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3882-e56a793670ceba918dca7cd90bfc472247ad93b59b931fe886964a3be006bb033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abacavir</topic><topic>Acquired immune deficiency syndrome</topic><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Adolescent</topic><topic>Adolescents</topic><topic>Adult</topic><topic>AIDS</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>Algorithms</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antibodies</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral therapy</topic><topic>Breast feeding</topic><topic>Cancer screening</topic><topic>Child</topic><topic>Cognitive ability</topic><topic>Comorbidity</topic><topic>COVID-19</topic><topic>Diabetes mellitus</topic><topic>Disease transmission</topic><topic>Drug interaction</topic><topic>Drug interactions</topic><topic>EACS</topic><topic>Emtricitabine</topic><topic>European AIDS Clinical Society</topic><topic>Guidelines</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>HIV</topic><topic>HIV Infections - diagnosis</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Integrase</topic><topic>Lamivudine</topic><topic>Lamivudine - therapeutic use</topic><topic>major updates</topic><topic>Medical screening</topic><topic>Monkeypox</topic><topic>Mpox</topic><topic>Mpox (monkeypox)</topic><topic>Practice Guidelines as Topic</topic><topic>Sexual health</topic><topic>Sexually transmitted diseases</topic><topic>STD</topic><topic>Tenofovir</topic><topic>Tenofovir - therapeutic use</topic><topic>V12.0</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ambrosioni, Juan</creatorcontrib><creatorcontrib>Levi, Laura</creatorcontrib><creatorcontrib>Alagaratnam, Jasmini</creatorcontrib><creatorcontrib>Van Bremen, Kathrin</creatorcontrib><creatorcontrib>Mastrangelo, Andrea</creatorcontrib><creatorcontrib>Waalewijn, Hylke</creatorcontrib><creatorcontrib>Molina, Jean‐Michel</creatorcontrib><creatorcontrib>Guaraldi, Giovanni</creatorcontrib><creatorcontrib>Winston, Alan</creatorcontrib><creatorcontrib>Boesecke, Christoph</creatorcontrib><creatorcontrib>Cinque, Paola</creatorcontrib><creatorcontrib>Bamford, Alasdair</creatorcontrib><creatorcontrib>Calmy, Alexandra</creatorcontrib><creatorcontrib>Marzolini, Catia</creatorcontrib><creatorcontrib>Martínez, Esteban</creatorcontrib><creatorcontrib>Oprea, Cristiana</creatorcontrib><creatorcontrib>Welch, Steven</creatorcontrib><creatorcontrib>Koval, Anna</creatorcontrib><creatorcontrib>Mendao, Luis</creatorcontrib><creatorcontrib>Rockstroh, Jürgen K.</creatorcontrib><creatorcontrib>EACS Governing Board</creatorcontrib><creatorcontrib>The EACS Governing Board</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ambrosioni, Juan</au><au>Levi, Laura</au><au>Alagaratnam, Jasmini</au><au>Van Bremen, Kathrin</au><au>Mastrangelo, Andrea</au><au>Waalewijn, Hylke</au><au>Molina, Jean‐Michel</au><au>Guaraldi, Giovanni</au><au>Winston, Alan</au><au>Boesecke, Christoph</au><au>Cinque, Paola</au><au>Bamford, Alasdair</au><au>Calmy, Alexandra</au><au>Marzolini, Catia</au><au>Martínez, Esteban</au><au>Oprea, Cristiana</au><au>Welch, Steven</au><au>Koval, Anna</au><au>Mendao, Luis</au><au>Rockstroh, Jürgen K.</au><aucorp>EACS Governing Board</aucorp><aucorp>The EACS Governing Board</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2023-11</date><risdate>2023</risdate><volume>24</volume><issue>11</issue><spage>1126</spage><epage>1136</epage><pages>1126-1136</pages><issn>1464-2662</issn><issn>1468-1293</issn><eissn>1468-1293</eissn><abstract>Background
The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.
Key Points of the Guidelines Update
Version 12.0 of the guidelines recommend the same six first‐line treatment options for antiretroviral treatment (ART)‐naïve adults as versions 11.0 and 11.1: tenofovir‐based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long‐acting section has been expanded in the ART and drug–drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti‐infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient‐reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir‐free two‐drug regimens in people with isolated anti‐hepatitis B core antibodies are provided. In the opportunistic infections and COVID‐19 panel, guidance on the management of COVID‐19 in people with HIV has been updated according to the most up‐to‐date evidence, and a new section on monkeypox has been added.
Conclusions
In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37849432</pmid><doi>10.1111/hiv.13542</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-5847-8416</orcidid><orcidid>https://orcid.org/0000-0003-2448-5957</orcidid><orcidid>https://orcid.org/0000-0002-5135-8729</orcidid><orcidid>https://orcid.org/0000-0001-9931-6686</orcidid><orcidid>https://orcid.org/0000-0003-2256-423X</orcidid><orcidid>https://orcid.org/0000-0002-5724-3914</orcidid><orcidid>https://orcid.org/0000-0003-4764-229X</orcidid><orcidid>https://orcid.org/0000-0001-9581-2527</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2023-11, Vol.24 (11), p.1126-1136 |
| issn | 1464-2662 1468-1293 1468-1293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2878713351 |
| source | Access via Wiley Online Library; MEDLINE |
| subjects | Abacavir Acquired immune deficiency syndrome Acquired Immunodeficiency Syndrome - drug therapy Adolescent Adolescents Adult AIDS AIDS-Related Opportunistic Infections - drug therapy Algorithms Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - therapeutic use Antibodies Antiretroviral agents Antiretroviral therapy Breast feeding Cancer screening Child Cognitive ability Comorbidity COVID-19 Diabetes mellitus Disease transmission Drug interaction Drug interactions EACS Emtricitabine European AIDS Clinical Society Guidelines Hepatitis Hepatitis B Hepatitis C Hepatitis C - drug therapy HIV HIV Infections - diagnosis HIV Infections - drug therapy Human immunodeficiency virus Humans Infections Integrase Lamivudine Lamivudine - therapeutic use major updates Medical screening Monkeypox Mpox Mpox (monkeypox) Practice Guidelines as Topic Sexual health Sexually transmitted diseases STD Tenofovir Tenofovir - therapeutic use V12.0 Vaccination Vaccines Viral diseases Viruses |
| title | Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T23%3A39%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Major%20revision%20version%2012.0%20of%20the%20European%20AIDS%20Clinical%20Society%20guidelines%202023&rft.jtitle=HIV%20medicine&rft.au=Ambrosioni,%20Juan&rft.aucorp=EACS%20Governing%20Board&rft.date=2023-11&rft.volume=24&rft.issue=11&rft.spage=1126&rft.epage=1136&rft.pages=1126-1136&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/hiv.13542&rft_dat=%3Cproquest_cross%3E2889744892%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2889744892&rft_id=info:pmid/37849432&rfr_iscdi=true |